AC   CVCL_4783
SY   LNCaP-C4; LNCaPC4; LNCaP subline C4; C4
DR   ATCC; CRL-3313
DR   BTO; BTO:0005868
DR   Wikidata; Q54902813
RX   PubMed=8169003;
RX   PubMed=12725112;
CC   Characteristics: Derived from a tumor that developed in castrated nude mice injected with LNCaP cells.
CC   Doubling time: 26.30 hours (!Synapse:syn2347014).
CC   Sequence variation: Homozygous for AR p.Thr878Ala (c.2632A>G) (from parent cell line).
CC   Sequence variation: Heterozygous for MEN1 p.Tyr313Ter (c.939T>A) (from parent cell line).
CC   Sequence variation: Heterozygous for PIK3R1 p.Arg639Ter (c.1915C>T) (from parent cell line).
CC   Derived from metastatic site: Left supraclavicular lymph node.
ST   Source(s): ATCC
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 10,11
ST   D16S539: 11
ST   D5S818: 11,12
ST   D7S820: 9,9.1,10.3
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 16,18,19
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 15
RX   PubMed=8169003; DOI=10.1002/ijc.2910570319;
RA   Wu H.-C., Hsieh J.-T., Gleave M.E., Brown N.M., Pathak S.,
RA   Chung L.W.K.;
RT   "Derivation of androgen-independent human LNCaP prostatic cancer cell
RT   sublines: role of bone stromal cells.";
RL   Int. J. Cancer 57:406-412(1994).
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).